These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38643339)

  • 1. Tumour-associated myeloid cells expressing IL-10R2/IL-22R1 as a potential biomarker for diagnosis and recurrence of pancreatic ductal adenocarcinoma.
    Lee HK; Kim SY; Chung SH; Choi B; Kim JE; Yoon D; Jang SI; Yeo A; Kang HG; Lee J; Choi YH; Park JS; Sung Y; Kim JK; Chang EJ; Lee DK
    Br J Cancer; 2024 Jun; 130(12):1979-1989. PubMed ID: 38643339
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pancreatic Ductal Adenocarcinoma (PDAC) circulating tumor cells influence myeloid cell differentiation to support their survival and immunoresistance in portal vein circulation.
    Arnoletti JP; Reza J; Rosales A; Monreal A; Fanaian N; Whisner S; Srivastava M; Rivera-Otero J; Yu G; Phanstiel Iv O; Altomare DA; Tran Q; Litherland SA
    PLoS One; 2022; 17(3):e0265725. PubMed ID: 35316296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Deciphering the Prognostic Implications of the Components and Signatures in the Immune Microenvironment of Pancreatic Ductal Adenocarcinoma.
    Tang R; Liu X; Liang C; Hua J; Xu J; Wang W; Meng Q; Liu J; Zhang B; Yu X; Shi S
    Front Immunol; 2021; 12():648917. PubMed ID: 33777046
    [No Abstract]   [Full Text] [Related]  

  • 4. The expression of β-Defensin-2, IL-22, IL-22R1 and IL-10R2 in rat model of
    Fan J; Luo Y; Qin Y; Wu C; Han X; Ouyang H; Zhang L; Cai P; Li N
    Exp Lung Res; 2020; 46(5):109-116. PubMed ID: 32169023
    [No Abstract]   [Full Text] [Related]  

  • 5. Analysis of Blood Plasma MicroRNAs to Enable Identification of Patients with Pancreatic Ductal Adenocarcinoma Who Will Benefit from Surgical Resection.
    Gablo N. A; Procházka V; Hlavsa J; Kiss I; Srovnal J; Kala Z; Slabý O
    Klin Onkol; 2019; 32(Suppl 1):174-176. PubMed ID: 31064193
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Infiltrating immune cells and gene mutations in pancreatic ductal adenocarcinoma.
    Wang WQ; Liu L; Xu HX; Wu CT; Xiang JF; Xu J; Liu C; Long J; Ni QX; Yu XJ
    Br J Surg; 2016 Aug; 103(9):1189-99. PubMed ID: 27256393
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3.
    Trovato R; Fiore A; Sartori S; Canè S; Giugno R; Cascione L; Paiella S; Salvia R; De Sanctis F; Poffe O; Anselmi C; Hofer F; Sartoris S; Piro G; Carbone C; Corbo V; Lawlor R; Solito S; Pinton L; Mandruzzato S; Bassi C; Scarpa A; Bronte V; Ugel S
    J Immunother Cancer; 2019 Sep; 7(1):255. PubMed ID: 31533831
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inflammatory cytokines and combined biomarker panels in pancreatic ductal adenocarcinoma: Enhancing diagnostic accuracy.
    Kruger D; Yako YY; Devar J; Lahoud N; Smith M
    PLoS One; 2019; 14(8):e0221169. PubMed ID: 31415645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosome-encapsulated microRNA-4525, microRNA-451a and microRNA-21 in portal vein blood is a high-sensitive liquid biomarker for the selection of high-risk pancreatic ductal adenocarcinoma patients.
    Kawamura S; Iinuma H; Wada K; Takahashi K; Minezaki S; Kainuma M; Shibuya M; Miura F; Sano K
    J Hepatobiliary Pancreat Sci; 2019 Feb; 26(2):63-72. PubMed ID: 30561106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improved predictability of pancreatic ductal adenocarcinoma diagnosis using a blood immune cell biomarker panel developed from bulk mRNA sequencing and single-cell RNA-sequencing.
    Jang SI; Lee HK; Chang EJ; Kim S; Kim SY; Hong IY; Kim JK; Lee HS; Yang J; Cho JH; Lee DK
    Cancer Immunol Immunother; 2023 Aug; 72(8):2757-2768. PubMed ID: 37165046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression.
    Chang DZ; Ma Y; Ji B; Liu Y; Hwu P; Abbruzzese JL; Logsdon C; Wang H
    J Hematol Oncol; 2012 Apr; 5():15. PubMed ID: 22475564
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasma biomarkers for prediction of early tumor recurrence after resection of pancreatic ductal adenocarcinoma.
    Rittmann MC; Hussung S; Braun LM; Klar RFU; Biesel EA; Fichtner-Feigl S; Fritsch R; Wittel UA; Ruess DA
    Sci Rep; 2021 Apr; 11(1):7499. PubMed ID: 33820913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of tumour and serum specific microRNA changes dissecting their role in pancreatic ductal adenocarcinoma: a meta-analysis.
    Chhatriya B; Mukherjee M; Ray S; Sarkar P; Chatterjee S; Nath D; Das K; Goswami S
    BMC Cancer; 2019 Dec; 19(1):1175. PubMed ID: 31795960
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Noninvasive detection of pancreatic ductal adenocarcinoma using the methylation signature of circulating tumour DNA.
    Wu H; Guo S; Liu X; Li Y; Su Z; He Q; Liu X; Zhang Z; Yu L; Shi X; Gao S; Wang H; Pan Y; Ma C; Liu R; Dai M; Jin G; Liang Z
    BMC Med; 2022 Nov; 20(1):458. PubMed ID: 36434648
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating extracellular vesicle-encapsulated HULC is a potential biomarker for human pancreatic cancer.
    Takahashi K; Ota Y; Kogure T; Suzuki Y; Iwamoto H; Yamakita K; Kitano Y; Fujii S; Haneda M; Patel T; Ota T
    Cancer Sci; 2020 Jan; 111(1):98-111. PubMed ID: 31715081
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reg proteins promote acinar-to-ductal metaplasia and act as novel diagnostic and prognostic markers in pancreatic ductal adenocarcinoma.
    Li Q; Wang H; Zogopoulos G; Shao Q; Dong K; Lv F; Nwilati K; Gui XY; Cuggia A; Liu JL; Gao ZH
    Oncotarget; 2016 Nov; 7(47):77838-77853. PubMed ID: 27788482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Downregulation of miR-124 predicts poor prognosis in pancreatic ductal adenocarcinoma patients.
    Sun B; Liu X; Gao Y; Li L; Dong Z
    Br J Biomed Sci; 2016 Oct; 73(4):152-157. PubMed ID: 27922430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SST gene hypermethylation acts as a pan-cancer marker for pancreatic ductal adenocarcinoma and multiple other tumors: toward its use for blood-based diagnosis.
    Manoochehri M; Wu Y; Giese NA; Strobel O; Kutschmann S; Haller F; Hoheisel JD; Moskalev EA; Hackert T; Bauer AS
    Mol Oncol; 2020 Jun; 14(6):1252-1267. PubMed ID: 32243066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.